Key opportunities in the animal vaccines market include addressing livestock disease outbreaks, leveraging next-gen mRNA technology, and reinforcing the One Health approach for zoonotic prevention. With rising global trade demands, biosecurity and advanced vaccine solutions, especially in emerging markets, are essential.
Animal Vaccines Market
Dublin, May 27, 2026 (GLOBE NEWSWIRE) — The “Animal Vaccines Market Size, Share & Trends Analysis Report by Product, Animal, Route of Administration, Distribution Channel, Region, and Growth Forecasts, 2026-2033” has been added to ResearchAndMarkets.com’s offering.
The global animal vaccines market size was estimated at USD 14.8 billion in 2025 and is expected to reach USD 32.4 billion by 2033, growing at a CAGR of 10.5% from 2026 to 2033. Key factors driving this growth include increasing cattle disease outbreaks, advancements in innovative therapies, and an emphasis on the One Health approach & zoonotic disease prevention.
The rising frequency and severity of livestock disease outbreaks are significantly increasing global demand for animal vaccines. Diseases like foot-and-mouth disease (FMD), avian influenza, African swine fever, and lumpy skin disease have caused substantial economic losses and disruptions to food supply chains. For instance, African Swine Fever led to over USD 112.5 billion in losses in 2019, while FMD results in annual losses of USD 21 billion globally. Governments and international bodies are implementing large-scale immunization programs to manage outbreaks and prevent transnational disease transmission. Rising global trade in livestock products necessitates rigorous biosecurity and vaccination protocols, especially in developing economies where livestock farming is crucial to livelihoods.
The emergence of mRNA and next-generation vaccine technologies is revolutionizing the market by enabling faster, more efficient, and targeted vaccine development. mRNA-based platforms allow rapid design and scalability, proving effective against emerging and mutating pathogens. In July 2025, an mRNA FMD vaccine developed with the Friedrich-Loeffler-Institut showed full protection in cattle, demonstrating its advantages over traditional methods. These advanced vaccines offer improved safety profiles and enhanced immune responses across companion and livestock animals, with significant investment from biopharmaceutical companies in RNA-based, recombinant, and vector-based vaccines addressing complex veterinary needs. The integration of advanced manufacturing technologies supports large-scale production and commercialization.